Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The most common typically strongest in the first 48 weeks as the body adapts include: Nausea (most common, usually dose-dependent) Diarrhoea or constipation Fatigue , especially during dose escalations Mild headache Reflux and acid reflux Loss of appetite (this is the therapeutic effect, not a side effect, but it can be uncomfortable) Less common but more serious effects warranting immediate physician review include pancreatitis, gallbladder disease, and kidney issues, particularly in patients with pre-existing conditions
GLP-1 receptor agonists also slow gastric emptying, which moderates the postprandial glucose spike and promotes satiety through central nervous system pathways
Crefcoeur LL, Melles MC, Bruning TA, et al
A history of these conditions does not automatically end the conversation, but it may change the calculus, prompt additional evaluation, or lead a clinician toward a different approach
MT-II itself has no regulatory approval for any indication and is not the same molecule as the approved bremelanotide product
US$ 26.45
US$ 24.34
US$ 28.47
US$ 24.83
US$ 28.50
US$ 21.06
US$ 29.89
